Cabazitaxel-induced stabilization of microtubules enhances radiosensitivity in ovarian cancer cells.

ABSTRACT:

Background

Up to 40% of women with ovarian cancer have short disease-free intervals due to molecular mechanisms of chemotherapy resistance. New therapeutic strategies are sought. Ovarian cancers are sensitive to radiochemotherapy. The taxane cabazitaxel (XRP6258, Jevtana) promotes tubulin assembly and stabilizes microtubules against depolymerization in cells, acting similarly in mechanism to paclitaxel. Here, sequences of cabazitaxel-radiation co-administration are tested for drug-alone cytotoxicity and optimal radiosensitization.

Materials and methods

SKOV3, OVCAR3, and TOV-112D ovarian cancer cells were administered cabazitaxel 24 h before (first), 18 h before (second), together (third), or 24 h after (fourth) a single radiation dose, and then, investigated by clonogenic a

SUBMITTER: Kunos CA 

PROVIDER: S-EPMC3776429 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature